阿维鲁马布一线维持治疗：管理晚期膀胱上皮癌患者
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
发表日期：2023 Jan 25
作者：
Maira Lapuente, Dawn Conway, Laura S Wood, Kiran Kehoe, Andrea Carroll Bullock, Geeta Devgan, Kathleen D Burns
来源：
Burns & Trauma
摘要：
JAVELIN膀胱癌100试验的三期结果表明，与仅最佳支持性治疗相比，avelumab一线维持治疗明显延长了总生存期。对于未进展的一线铂类化疗适应症患者，这已经成为标准护理方法，该患者患有局部晚期或转移性尿路上皮癌。本文提供了对肿瘤科护士在临床环境中有效实施avelumab一线维持治疗的考虑。本文回顾了有关临床证据和对接受avelumab一线维持治疗患者的肿瘤学护理人员的意义。肿瘤学护理人员可以通过对患者和护理人员进行教育，确保正确给药，并及时识别和管理免疫相关不良事件，为患有晚期尿路上皮癌的患者提供综合护理，并确保avelumab一线维持治疗的安全和合理使用。
The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.Oncology nurses can provide comprehensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct administration, and promptly recognizing and managing immune-related adverse events.